PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22031231-0	2012	Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival.	Vinorelbine	83-94	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	4-9	
22031231-1	2012	INTRODUCTION: The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial.	Vinorelbine	195-206	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	39-84	
22031231-1	2012	INTRODUCTION: The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial.	Vinorelbine	195-206	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	86-91	
22031231-13	2012	CONCLUSION: Our retrospective study in MPM patients treated with cisplatin/vinorelbine suggests that low ERCC1 expression, evaluated by IHC, may predict longer PFS, a result that warrants further validation.	Vinorelbine	75-86	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	105-110